I find that the discussion reads more as a re-hash of the already extensive results section. There is little critical analysis of the impact of the past 50 years' research on current and future clinical practice and research. Benefiting from the synthesis of their thorough review, please include some discussion of the following: 1. Where do the the glaring weaknesses or gaps in knowledge reside in our current approach? Acknowledging the impossibility of covering every potential causative agent, are there specific areas or diagnostic methods which offer promise? The authors discuss clinical presenting signs, imaging studies, and laboratory data as the available means of AP detection. Is there, or should there be, an emphasis on any individual modality as a more effective way to establish the disease?
Introduction
The information on lines 6 to 15 could be omitted, since this data is well known. I suggest: "Approximately 0.1 to 2.0% of acute pancreatitis (AP) cases have a medication-related cause. With over a hundred medications associated with AP in the literature, the list of medications potentially associated with AP will continue to expand as new drugs are marketed..."
Data extraction
Have you contacted the researchers for additional data? Researchers of the included studies published after 2012 with no AP diagnostic criteria described could be contacted in order to identify criteria used and not described.
Discussion
Only studies in English, Spanish and French where included, perhaps you should mention it as a selection bias.
VERSION 1 -AUTHOR RESPONSE

Reviewer 1 Feedback and Responses
This is a well-designed and rigorously executed systematic review examining the diagnostic process of drug-induced acute pancreatitis. The authors have done a wonderful and comprehensive job and I commend them on their work. The manuscript is very near publishable status, but I have a few questions mainly regarding the discussion section. I find that the discussion reads more as a re-hash of the already extensive results section. There is little critical analysis of the impact of the past 50 years' research on current and future clinical practice and research. Benefiting from the synthesis of their thorough review, please include some discussion of the following: 1. Where do the the glaring weaknesses or gaps in knowledge reside in our current approach? Acknowledging the impossibility of covering every potential causative agent, are there specific areas or diagnostic methods which offer promise? The authors discuss clinical presenting signs, imaging studies, and laboratory data as the available means of AP detection. Is there, or should there be, an emphasis on any individual modality as a more effective way to establish the disease?
• Response: In our comprehensive search of the literature, we did not identify any upcoming diagnostic methods that offer promise. Currently, the three components of the accepted diagnostic criteria must be used together to establish confirmation of a diagnosis of clinical acute pancreatitis. No specific component should be emphasized, unless identification of subclinical cases is an objective, wherein clinical signs/symptoms need not be considered.
2. Along those same lines, in which realm should future research focus? Should genetic or laboratory testing focus on a more consistent, quick detection method?
• Response: We agree and have added text to the discussion section of the manuscript to address future research goals as per this suggestion. We have added the following text: "Future research efforts in identifying more specific biomarkers for earlier identification of pancreatitis or pharmacogenomic testing to identify a higher risk group of patients in whom a greater risk of pancreatitis could be predicted would useful to clinicians, trialists and regulatory bodies. In research as well as in clinical practice, until biomarkers for DIP are developed,In the meantime, reliance on heightened clinical awareness, identification of high-risk patients, and the use of standardized diagnostic and causality criteria remain key to DIP detection and diagnosis."
3. The authors mention that, although diagnostic criteria are well-established and generally accepted, researchers often do not comply with these criteria in their own research. Why is this? Are studies biased in their efforts to encompass all cases of AP? If the approach is further standardized across studies, how would this impact results? Moreover, what should be done to promote alignment between studies regarding diagnostic criteria?
• Response: It is unclear why well-established and generally accepted diagnostic criteria would not be used by all researchers. The objective of our review was focused on defining recommendations for detection processes for DIP, if any recommendations had been made. We secondarily reviewed what diagnostic processes had been used by researchers in peer-reviewed trials that had diagnosis of drug-induced pancreatitis as an outcome of interest and that sufficiently described the diagnostic process. We assume that, as time goes by, uptake of the diagnostic criteria would become broader due to increased awareness. We cannot predict how uptake of the accepted criteria may impact results; however, we have added an in-depth paragraph within the manuscript's Discussion section describing how potentially lack of use of the accepted criteria may have prevented confirmation of an association between a drug and pancreatitis during the FDA new drug approval process. Use of the accepted criteria could be recommended by regulatory agencies to researchers/trialists during preapproval clinical trials to promote use of the criteria.
A minor comment: please denote roles of authors in the review and inclusion/exclusion process.
• Response: The roles of the authors have been provided in the Authors' Contributions section. All components of the review process (screening, data extraction, synthesis) have been included.
Reviewer 2 Feedback and Responses
Congratulations on a lot of work to produce a robust systematic review on methods for early detection of DIP. The study is relevant and the first review published that have evaluated DIP detection and diagnostic processes. The design of the study is adequate, the search is acceptably performed and the included studies discussed and synthesised adequately. The discussion of risk of bias has been addressed and the results have been interpreted sufficiently. The study also shed a light on the lack of standardized diagnosis of DIP and the low uptake of AP diagnostic criteria even in recent studies, leading to misdiagnosis of AP and incorrect attribution of cause to a drug when it is not. Below are some questions and recommendations and reflections.
1. Introduction: The information on lines 6 to 15 could be omitted, since this data is well known. I suggest: "Approximately 0.1 to 2.0% of acute pancreatitis (AP) cases have a medication-related cause. With over a hundred medications associated with AP in the literature, the list of medications potentially associated with AP will continue to expand as new drugs are marketed..."
• Response: We appreciate the reviewer's comment, though we very politely disagree. We feel that it is important to keep that paragraph intact in order build an argument regarding the importance of the problem. Without the associated text, we feel that the flow of the introduction would become choppy and we would rather not assume that all readers are familiar enough with the context of our research question. If the reviewer or editor feels strongly about this point, we would be more than happy to reconsider further.
Regarding Data extraction:
• Response: One of the criteria for inclusion of studies in this review was that a sufficient description of the process to detect or diagnose DIP must have been reported. We excluded 148 studies for not sufficiently reporting a process, of which 40 were published after 2012, when the international consensus criteria were revised and published. Unfortunately, contacting each of these studies' authors was not within our project budget or timelines.
3. Regarding Discussion Section: Only studies in English, Spanish and French where included, perhaps you should mention it as a selection bias.
• Response: We respectfully disagree with the reviewer's opinion that inclusion of English, French, and Spanish literature was a limitation of the study resulting in selection bias. Guidance from the Cochrane Handbook, which cites several studies, indicates that language bias may only be important in reviews that include only English-language papers. Thus, we feel that by also including French-and Spanish-language literature, our review was not significantly biased to warrant mentioning this as a limitation in the Discussion. For reference, as noted on the Cochrane Handbook website (http://handbook-5-1.cochrane.org/), section 10.2.2.4 on Language Bias, the extent and effects of language bias in reviews that include only English-language literature may have diminished recently because of the shift towards publication of studies in English.
VERSION 2 -REVIEW
REVIEWER
Mark Jones, MD Harvard Medical School USA REVIEW RETURNED 08-Oct-2019
GENERAL COMMENTS
Thank you for updating the paper per previous review. Now acceptable for publication.
